RT Journal Article
SR Electronic
T1 Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.20.20215855
DO 10.1101/2020.10.20.20215855
A1 Storm, Catherine S.
A1 Kia, Demis A.
A1 Almramhi, Mona
A1 Athauda, Dilan
A1 International Parkinson’s Disease Genomics Consortium (IPDGC)
A1 Burgess, Stephen
A1 Foltynie, Thomas
A1 Wood, Nicholas W.
YR 2020
UL http://medrxiv.org/content/early/2020/10/21/2020.10.20.20215855.abstract
AB Background Exenatide is a glucagon-like peptide 1 receptor (GLP1R) agonist used in type 2 diabetes mellitus that has shown promise for Parkinson’s disease in a phase II clinical trial. Drugs with genetic evidence are more likely to be successful in clinical trials. In this study we investigated whether the genetic technique Mendelian randomization (MR) can “rediscover” the effects of exenatide on diabetes and weight, and predict its efficacy for Parkinson’s disease.Methods We used genetic variants associated with increased expression of GLP1R in blood to proxy exenatide, as well as variants associated with expression of DPP4, TLR4 and 15 genes thought to act downstream of GLP1R or mimicking alternative actions of GLP-1 in blood and brain tissue. Using an MR approach, we predict the effect of exenatide on type 2 diabetes risk, body mass index (BMI), Parkinson’s disease risk and several Parkinson’s disease progression markers.Results We found that genetically-raised GLP1R expression in blood was associated with lower BMI and possibly type 2 diabetes mellitus risk, but not Parkinson’s disease risk, age at onset or progression. Reduced DPP4 expression in brain tissue was significantly associated with increased Parkinson’s disease risk.Conclusions We demonstrate the usefulness of MR using expression data in predicting the efficacy of a drug and exploring its mechanism of action. Our data suggest that GLP-1 mimetics like exenatide, if ultimately proven to be effective in Parkinson’s disease, will be through a mechanism that is independent of GLP1R in blood.Competing Interest StatementDA and TF are investigators on the Exenatide-PD and Exenatide-MSA trials. The other authors declare no competing interests. No funders had a role in the writing or decision to submit this manuscript for publication.Funding StatementNo funders had a role in the design, data collection, analysis, interpretation, writing nor decision to submit this study. CSS is funded by Rosetrees Trust, John Black Charitable Foundation and the University College London MBPhD Programme. DAK is supported by an MBPhD Award from the International Journal of Experimental Pathology. MA is funded by the Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. NWW is a National Institute for Health Research senior investigator and receives support from the European Union Joint Programme Neurodegenerative Disease Research Medical Research Council Comprehensive Unbiased Risk factor Assessment for Genetics and Environment in Parkinsons disease. NWW receives support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. See supplementary notes for IPDGC Funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe GWAS data used by this study are publicly available as stated in the original publications. The supplementary information contains full results. We make our code openly available at https://github.com/catherinestorm/mr_exenatide.